211 related articles for article (PubMed ID: 21846842)
1. Monitoring a nuclear factor-κB signature of drug resistance in multiple myeloma.
Xiang Y; Remily-Wood ER; Oliveira V; Yarde D; He L; Cheng JQ; Mathews L; Boucher K; Cubitt C; Perez L; Gauthier TJ; Eschrich SA; Shain KH; Dalton WS; Hazlehurst L; Koomen JM
Mol Cell Proteomics; 2011 Nov; 10(11):M110.005520. PubMed ID: 21846842
[TBL] [Abstract][Full Text] [Related]
2. Targeting the Fanconi anemia/BRCA pathway circumvents drug resistance in multiple myeloma.
Yarde DN; Oliveira V; Mathews L; Wang X; Villagra A; Boulware D; Shain KH; Hazlehurst LA; Alsina M; Chen DT; Beg AA; Dalton WS
Cancer Res; 2009 Dec; 69(24):9367-75. PubMed ID: 19934314
[TBL] [Abstract][Full Text] [Related]
3. The FA/BRCA pathway is involved in melphalan-induced DNA interstrand cross-link repair and accounts for melphalan resistance in multiple myeloma cells.
Chen Q; Van der Sluis PC; Boulware D; Hazlehurst LA; Dalton WS
Blood; 2005 Jul; 106(2):698-705. PubMed ID: 15802532
[TBL] [Abstract][Full Text] [Related]
4. Proteometabolomics of Melphalan Resistance in Multiple Myeloma.
Koomen DC; Guingab-Cagmat JD; Oliveira PS; Fang B; Liu M; Welsh EA; Meads MB; Nguyen T; Meke L; Eschrich SA; Shain KH; Garrett TJ; Koomen JM
Methods Mol Biol; 2019; 1996():273-296. PubMed ID: 31127562
[TBL] [Abstract][Full Text] [Related]
5. Genotypic and phenotypic comparisons of de novo and acquired melphalan resistance in an isogenic multiple myeloma cell line model.
Hazlehurst LA; Enkemann SA; Beam CA; Argilagos RF; Painter J; Shain KH; Saporta S; Boulware D; Moscinski L; Alsina M; Dalton WS
Cancer Res; 2003 Nov; 63(22):7900-6. PubMed ID: 14633719
[TBL] [Abstract][Full Text] [Related]
6. Integrin β7-mediated regulation of multiple myeloma cell adhesion, migration, and invasion.
Neri P; Ren L; Azab AK; Brentnall M; Gratton K; Klimowicz AC; Lin C; Duggan P; Tassone P; Mansoor A; Stewart DA; Boise LH; Ghobrial IM; Bahlis NJ
Blood; 2011 Jun; 117(23):6202-13. PubMed ID: 21474670
[TBL] [Abstract][Full Text] [Related]
7. An inverse switch in DNA base excision and strand break repair contributes to melphalan resistance in multiple myeloma cells.
Sousa MM; Zub KA; Aas PA; Hanssen-Bauer A; Demirovic A; Sarno A; Tian E; Liabakk NB; Slupphaug G
PLoS One; 2013; 8(2):e55493. PubMed ID: 23405159
[TBL] [Abstract][Full Text] [Related]
8. Frequent engagement of RelB activation is critical for cell survival in multiple myeloma.
Cormier F; Monjanel H; Fabre C; Billot K; Sapharikas E; Chereau F; Bordereaux D; Molina TJ; Avet-Loiseau H; Baud V
PLoS One; 2013; 8(3):e59127. PubMed ID: 23555623
[TBL] [Abstract][Full Text] [Related]
9. Nuclear factor-kappaB and STAT3 are constitutively active in CD138+ cells derived from multiple myeloma patients, and suppression of these transcription factors leads to apoptosis.
Bharti AC; Shishodia S; Reuben JM; Weber D; Alexanian R; Raj-Vadhan S; Estrov Z; Talpaz M; Aggarwal BB
Blood; 2004 Apr; 103(8):3175-84. PubMed ID: 15070700
[TBL] [Abstract][Full Text] [Related]
10. PJ34, a poly(ADP-ribose) polymerase (PARP) inhibitor, reverses melphalan-resistance and inhibits repair of DNA double-strand breaks by targeting the FA/BRCA pathway in multidrug resistant multiple myeloma cell line RPMI8226/R.
Xiong T; Wei H; Chen X; Xiao H
Int J Oncol; 2015 Jan; 46(1):223-32. PubMed ID: 25351371
[TBL] [Abstract][Full Text] [Related]
11. HSP70 inhibition reverses cell adhesion mediated and acquired drug resistance in multiple myeloma.
Nimmanapalli R; Gerbino E; Dalton WS; Gandhi V; Alsina M
Br J Haematol; 2008 Aug; 142(4):551-61. PubMed ID: 18503584
[TBL] [Abstract][Full Text] [Related]
12. Modulation of cell metabolic pathways and oxidative stress signaling contribute to acquired melphalan resistance in multiple myeloma cells.
Zub KA; Sousa MM; Sarno A; Sharma A; Demirovic A; Rao S; Young C; Aas PA; Ericsson I; Sundan A; Jensen ON; Slupphaug G
PLoS One; 2015; 10(3):e0119857. PubMed ID: 25769101
[TBL] [Abstract][Full Text] [Related]
13. Overexpression of HIF-1α contributes to melphalan resistance in multiple myeloma cells by activation of ERK1/2, Akt, and NF-κB.
Tsubaki M; Takeda T; Tomonari Y; Koumoto YI; Imano M; Satou T; Nishida S
Lab Invest; 2019 Jan; 99(1):72-84. PubMed ID: 30353128
[TBL] [Abstract][Full Text] [Related]
14. Bcl-2 overexpression is associated with resistance to dexamethasone, but not melphalan, in multiple myeloma cells.
Gazitt Y; Fey V; Thomas C; Alvarez R
Int J Oncol; 1998 Aug; 13(2):397-405. PubMed ID: 9664139
[TBL] [Abstract][Full Text] [Related]
15. The novel, proteasome-independent NF-kappaB inhibitor V1810 induces apoptosis and cell cycle arrest in multiple myeloma and overcomes NF-kappaB-mediated drug resistance.
Meinel FG; Mandl-Weber S; Baumann P; Leban J; Schmidmaier R
Mol Cancer Ther; 2010 Feb; 9(2):300-10. PubMed ID: 20124446
[TBL] [Abstract][Full Text] [Related]
16. Down-regulation of CD98 in melphalan-resistant myeloma cells with reduced drug uptake.
Harada N; Nagasaki A; Hata H; Matsuzaki H; Matsuno F; Mitsuya H
Acta Haematol; 2000; 103(3):144-51. PubMed ID: 10940652
[TBL] [Abstract][Full Text] [Related]
17. Importin β1 mediates nuclear factor-κB signal transduction into the nuclei of myeloma cells and affects their proliferation and apoptosis.
Yan W; Li R; He J; Du J; Hou J
Cell Signal; 2015 Apr; 27(4):851-9. PubMed ID: 25643631
[TBL] [Abstract][Full Text] [Related]
18. Alkylating agents induce activation of NFkappaB in multiple myeloma cells.
Baumann P; Mandl-Weber S; Oduncu F; Schmidmaier R
Leuk Res; 2008 Jul; 32(7):1144-7. PubMed ID: 18083229
[TBL] [Abstract][Full Text] [Related]
19. Chromatin structure, transcriptional activity and DNA repair efficiency affect the outcome of chemotherapy in multiple myeloma.
Gkotzamanidou M; Sfikakis PP; Kyrtopoulos SA; Bamia C; Dimopoulos MA; Souliotis VL
Br J Cancer; 2014 Sep; 111(7):1293-304. PubMed ID: 25051404
[TBL] [Abstract][Full Text] [Related]
20. c-MYC deregulation is involved in melphalan resistance of multiple myeloma: role of PDGF-BB.
Greco C; D'Agnano I; Vitelli G; Vona R; Marino M; Mottolese M; Zuppi C; Capoluongo E; Ameglio F
Int J Immunopathol Pharmacol; 2006; 19(1):67-79. PubMed ID: 16569345
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]